News
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...
Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...
5d
Investor's Business Daily on MSNIs Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
The results of South San Francisco-based Freenome Holdings Inc.’s 42,000-person study won’t be released until the second half of this year. But leaders of the privately held company and its ...
Freenome is conducting the PREEMPT CRC study, a >35,000-person prospective study for colorectal cancer (CRC) evaluating Freenome's blood-based screening test for CRC in the average-risk population.
Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results